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Abstract:

The potential of Raman micro spectroscopy as an in vitro, non-invasive tool for clinical
applications has been demonstrated in recent years, specifically for cancer research. To
further illustrate its potential as a high content and label free technique, it is important to
show its capability to elucidate drug mechanisms of action and cellular resistances. In this
study, cytotoxicity assays were employed to establish the toxicity profiles for 24hr exposure
of lung cancer cell lines, A549 and Calu-1, to the commercially available drug, doxorubicin
(DOX). Raman spectroscopy, coupled with Confocal Laser Scanning Microscopy and Flow
Cytometry, was used to track the DOX mechanism of action, at a subcellular level, and to
study the mechanisms of cellular resistance to DOX. Biomarkers related to the drug
mechanism of action and cellular resistance to apoptosis, namely reactive oxygen species
(ROS) and bcl-2 protein expression, respectively, were also measured and correlated to
Raman spectral profiles. Calu-1 cells are shown to exhibit spectroscopic signatures of both
direct DNA damage due to intercalation in the nucleus and indirect damage due to oxidative
stress in the cytoplasm, whereas the A549 cell line only exhibits signatures of the former
mechanism of action.

Abstract Figure:

PCA of nucleolar, nuclear and cytoplasmic regions of A549 and Calu-1 with corresponding
loadings of PC1 and PC2
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Introduction:

The potential of Raman micro spectroscopy as a non-destructive, label free, analytical
technique in clinical, pharmaceutical development and biomedical applications, based on its
ability to monitor the chemical, bio-physiological and physical changes at the molecular
level, has been demonstrated. [1-3]
Among the possible applications of Raman micro spectroscopy in the clinical setting, cancer
research and diagnostics remain among the most promising, including cancer detection and
typing, for example oral [4, 5], gastric [6, 7], breast [8, 9], cervical [10, 11], skin [12] cancers
as well as therapeutic follow up and response to chemotherapeutic drugs . [13, 14]
Indeed, Raman micro spectroscopy has been used not only to detect and monitor drugs inside
cells at a subcellular level but also to fingerprint the cellular response to this exposure and the
adverse drug effect [15]. Therefore, it can be developed as a companion diagnostic tool,
providing details about drug efficacy and safety, as detailed in the US FDA guidance
document issued in August 2014, which defines such a tool as an in vitro diagnostic device
that provides information that is essential for the safe and effective use of a corresponding
therapeutic product. [16, 17] The use of in vitro models is also consistent with EU and US
policies to reduce the use of animals for scientific testing (EU Directive-2010/63/EU and US
Public Law 106-545, 2010, 106th Congress) and thus the demonstration of Raman micro
spectroscopy as a companion diagnostic for screening and analysis of commercial
chemotherapeutic agents could be of significant importance in cancer research.
To this end, Doxorubicin (DOX), which belongs to the anthracycline family, commercially
known as Adriamycin, and widely prescribed as a chemotherapeutic antibiotic, was employed
as a model compound. Despite its extensive clinical use, DOX has many toxic and chronic
side effects, notably cardiotoxicity [18], and therefore it is important to understand how it
effects cancer cells and the sources of cellular resistance in order to optimise its clinical
efficacy and reduce its toxicity to the surrounding environment.
Routinely used clinically to treat aggressive and metastatic tumours, including lung cancers,
DOX involves different mechanisms of action, not fully understood. Although originally
thought to inhibit tumour cell proliferation by DNA intercalation, over the years, many other
mechanisms of action have been identified, such as topoisomerase II inhibition, the formation
of DNA adducts[19, 20], inhibition of DNA methyltransferase [21] and Transforming
Growth Factor-β1 (TGFβ1) [22] and oxidative stress by generation of reactive oxygen
species (ROS). The latter relates to its cytosolic metabolism and reduction to the doxorubicin

semiquinone radical, leading to generation of superoxide and hydrogen peroxide, increased
intracellular oxidative stress [23, 24], changes in the mitochondrial permeability, a release of
cytochrome C which activate caspase effectors causing DNA damage. [20, 25] All these
mechanisms of action lead to apoptosis, a programmed cell death or “cellular suicide”, as a
way to remove unwanted cells exhibiting dangerous anarchic development as tumour cells,
initiated extrinsically by the engagement of receptors at cytoplasmic membrane or
intrinsically by, for example, DNA damage, resulting from chemotherapy or oxidative stress
or growth factor withdrawal. [26-29]
The mitochondrial or intrinsic apoptosis pathway is controlled by two groups of proteins;
pro-apoptotic and anti-apoptotic. Among the latter category, the bcl-2 (B cell lymphoma)
family, an intracellular membrane protein generated as a direct result of DNA damage,
represents the most important anti-apoptotic protein, which binds to almost all pro-apoptotic
proteins [30] and so regulates the mitochondrial apoptosis pathways by mediating the
mitochondrial outer membrane permeability (MOMP) and by local inhibition of free radical
production suggesting an anti-oxidant mechanism, inhibiting cell apoptosis as a results
including drug-induced. [31-36]
Any alteration, resistance or failure in apoptosis, due for example, to a higher expression of
anti-apoptotic protein bcl-2, allows tumour cells to survive and proliferate, leading to
resistance to chemotherapy and a poor clinical prognosis. [37-39] The cytological
mechanisms of drug resistance in cancer cells can be an increased detoxification of anticancer
drugs by the glutathione system, a defective apoptotic pathway, enhanced DNA damage
repair or increased tolerance to DNA damage leading to suppression of apoptosis, elevated
expression of anti-apoptotic genes and proteins, decreased uptake of water-soluble drugs and
enhanced drug efflux from cancer cells mediated by ATP-binding cassette (ABC)
transporters. [40, 41]
Understanding the relative contributions of this array of potential contributing mechanisms is
a challenging task, requiring a manifold of parallel analytical techniques and assays, which
are costly and time consuming. Previous studies have shown that Raman micro spectroscopy
is not only able to discriminate between cancer cells according to nucleolar region [42] but
also to detect drugs inside cells, their effects on cell biology and the physiological response of
the cell to this exposure. [14] The aim of the current study extend the previous investigations
to fingerprint the DOX mechanism of action on non-small cell lung cancer cell lines A549
and Calu-1 and the different cellular response using Raman micro spectroscopy and to
investigate its ability to differentiate the effect of the chemotherapeutic drug in the two

different lung cancer cell lines. To support this spectroscopic analysis, Confocal Laser
Scanning Microscopy was employed to monitor the subcellular DOX localisation and bcl-2
expression due to DNA damage was measured using Flow Cytometry and correlated to
cellular levels of ROS, in relation to DOX mechanism of action. All observations were
related to changes in Raman features for the three cellular compartments nucleolus, nucleus
and cytoplasm.

Materials and methods:
Materials:
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were obtained
from ATTC (Manassas, VA, USA) and Calu-1 human lung epidermoid carcinoma cell line,
was kindly provided by Dr. Josep Sulé-Suso, Institute for Science & Technology in
Medicine, Keele University, Guy Hilton Research Centre UK and Cancer Centre, Royal
Stoke University Hospital, University Hospitals of North Midlands, UK.
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) was diluted in 1mL
sterile water to the required concentration (17.25 mM).
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.
For cytotoxicity assays an AB/MTT solution, 1.5mL of AB and 3 mL of MTT stock solution
(2.5mg/mL, 25mg MTT/10mL PBS) in 30mL of fresh medium was prepared.
Fixation/permeabilization kit, BD Cytofix/Cytoperm (BD 554714), and FITC Mouse AntiHuman bcl-2 set with an IgG1 isotype control (BD 556357) were purchased from BD
Biosciences, Ireland.
Nucred® live 647 ReadyProbes® Reagent, used to image the cellular nucleus, and [5(6)Carboxy-2',7'-dichlorodihydrofluorescein diacetate] (Carboxy-H2DCFDA) dye, used for the
detection of Reactive oxygen species (ROS), were both purchased from BioSciences, Ireland
(suppliers for Life Technologies).

Cell culture
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 10% foetal bovine serum
(FBS) and Calu-1 cells in RPMI with 10% FBS, both at 37°C in a humidified atmosphere
containing 5% CO2 and cells were split every two days to maintain ~60% confluence.

For Confocal Laser Scanning Fluorescence Microscopy (CLSM) and Raman micro
spectroscopic analysis, cell number was determined using a Beckman Coulter Particle Count
and Size Analysis® Z2 Cell Counter.

Cytotoxicity assays:
AB and MTT assays were performed in 96 well plates and a total number of 1x105 cells were
used to seed three plates (4x103 cells/mL). After 24h incubation, plates were washed with
phosphate buffered saline solution (PBS) and DOX was added in a concentration range from
0µM (as a control) to 50 µM.
AB and MTT assays were both measured with a Cytotox SpectraMax ®M3 plate reader using
Soft Max® Pro6.2.2 software. After 24h incubation in DOX, plates were washed with PBS
and 100µL of AB/MTT solution were added to each well. Plates were then incubated for 3
hours and AB fluorescence and MTT absorbance were measured in the plate reader using,
respectively, 540nm excitation, 595nm emission for AB and 570nm for MTT. All
cytotoxicity assays were made in triplicate and repeated three times and viability data was
fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values of the
mean inhibitory concentration, IC50.

Confocal Laser Scanning Fluorescence Microscopy:
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes
(MatTek Corporation, USA) for two hours, after which they were covered with cell culture
medium. After 24h incubation, the medium was removed and samples were rinsed twice with
sterile PBS, new fresh medium containing DOX corresponding to the median inhibitory
concentration, IC50, determined by cytotoxicity assays, was added and cells were incubated
for a further 24h. After incubation, old medium was removed and 2mL of Nucred® solution
in medium was added and, after 15 to 30 min incubation, samples were rinsed twice with
sterile PBS, fixed in formalin (4%, 15mn) and kept in PBS for imaging. Control samples
without exposure to DOX were also prepared in parallel, and incubated for 24h.
CLSM images were recorded using an inverted Zeiss LSM 510 confocal laser scanning
microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited
with an argon ion laser at 488 nm, and the emission was collected at 530 nm, while Nucred®
excitation and emission were respectively measured using 633 and 690 nm.

Flow Cytometry:
Cells (3x 104/flasks) were cultured in T25 flasks over 24h, and then exposed to a range of
DOX concentration (from 0.25x IC50 to 3.5x IC50). After 24h incubation, cells were
trypsinised and centrifuged in 5 mL fresh medium at 4°C and 1100 rpm for 5 min,
whereupon, they were re-suspended with 1mL ice cold Dulbecco's Phosphate-Buffered Saline
(DPBS) buffer and centrifuged at 4°C and 2500 rpm for 5 min.
Cells were re-suspended in 750 µL ice cold DPBS buffer and transferred to Eppendorf tubes
to which 250 µL of fixation buffer were added. After 30 min incubation at 4ºC, the fixed cells
were washed twice in perm/wash buffer, centrifuged (2500 Rpm for 5mn at 4ºC) and then
gently re-suspended in 50 µL perm/wash buffer, after which 20 µL of the antibody were
added and the cells were incubated for 60 min in the dark at 4ºC. The cells were then washed
twice in perm/wash buffer, centrifuged (2500 Rpm for 5mn at 4ºC) to remove unbound
antibody and finally re-suspended in 1mL stain buffer. 10,000 cells were analysed by Flow
Cytometry using a BD Biosciences Accuri C6 Flow Cytometer (Becton Dickinson, Oxford,
UK). The Accuri Flow cytometry software was used for the analysis of flow cytometry
samples and data processing.
Reactive oxygen species (ROS) expression:
Carboxy-H2DCFDA dye was employed for the detection and quantification of ROS
production in the intracellular environment. A solution at 10µM of Carboxy-H2DCFDA was
made up in PBS and added to the cells for 1hr incubation. After incubation, cells were
washed three times with PBS, then exposed to DOX for 24hrs. Fluorescence was measured in
the plate reader using 488nm excitation and 535nm emission.
Negative controls, consisting of healthy cells, untreated with DOX, analysed with or without
Carboxy-H2DCFDA and DOX treated cells analysed without Carboxy-H2DCFDA, as well
as positive controls of healthy cells exposed to a solution of hydrogen peroxide at 1µM, were
prepared in parallel.
Raman micro spectroscopy:
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) for
24h for both control and exposure to DOX. Medium was then removed and samples were
rinsed twice with sterile PBS and covered with DOX at the IC50. After 24h incubation, cells
were washed twice with sterile PBS and fixed in formalin (4%, 15min).

A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785nm, 300mW diode laser as
source (100mW at the sample), Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm
confocal hole, was used to record spectra from the two cell lines, in the range from 400 cm-1
to 1800 cm-1 using a x100 objective (LCPlanN, Olympus N.A. 0,85)), in dry conditions from
three cell locations: cytoplasm, nucleus and nucleolus, for 30s two times , to finally produce a
data set of 30 points per cell location (one spectrum from each cell compartment per cell) for
each control and exposure to DOX, over a total of 120 different cells.
Data analysis:
Raman spectral pre-processing and analysis were performed in Matlab 2013 using algorithms
developed in house. Prior to analysis, spectra were smoothed (Savitsky-Golay filter 5th order,
7 points), vector normalised, baseline corrected (fifth order polynomial) and background and
DOX spectral features were subtracted using a non-negatively constrained least squares
(NCLS) algorithm. [43]
After pre-processing, principal components analysis (PCA) was employed as an unsupervised
multivariate approach to analyse data and the effects of doxorubicin in each cell localisation
and in each cell line. The order of the PCs denotes their importance in the dataset, whereby
PC1 describes the highest amount of variation. [44]
Independent component analysis (ICA) was also employed as an extension to PCA. ICA is an
unsupervised statistical technique able to identify latent variables called independent
components. In case of Raman micro spectroscopy, ICA can be used to identify spectral
contributions such as those from substrate, using the same number of ICs as PCs, which can
then be removed or studied in their own right. [45, 46]

Results and discussion:

Cytotoxicity assays:
A.

B.

Figure 1: AB and MTT 24 hrs in vitro dose dependent cytotoxicity assays of DOX A. A549
and B. Calu-1. Viability is expressed as % compared to control, and the error bars indicate
the standard deviation of six independent replicate measurements
Figure 1 shows the dose dependant cytotoxicity of DOX after 24hrs exposure, for both cell
lines, A549 and Calu-1, according to the AB and MTT in vitro cytotoxicity assays. Viability
is expressed as % compared to control (non-exposed healthy cells), and the error bars indicate
the standard deviation of six independent replicate measurements.
For both in vitro assays, a partial loss of cell population viability is observed. However,
whereas the AB and MTT for the A549 cell line and the MTT assay for the Calu-1 cell line
show similar responses, the AB assay is relatively insensitive to the Calu-1 exposure. The
differences in the responses between AB and MTT in the two cell lines, as demonstrated by
Figure 1, suggest different sensitivities and/or resistances of the respective cell-lines to the
drug, and should be analysed in terms of the mode of response of the assays.
The MTT test is a colorimetric assay that measures the reduction of yellow 3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate
dehydrogenase into purple formazan crystals, insoluble in aqueous solution. [47, 48]
Succinate dehydrogenase or succinate-coenzyme Q reductase (SQR) or respiratory Complex
II is an enzyme complex, bound to the inner mitochondrial membrane of mammalian
mitochondria and many bacterial cells. It is the only enzyme that participates in both the citric
acid cycle and the electron transport chain, so the MTT assay is the reflection of
mitochondrial activity. Alamar blue (AB), on the other hand, is a water-soluble dye and one
of the most highly used cytotoxicity assays for in vitro quantification of the cell viability. [49]
When added to cell cultures, the active dye, resazurin or 7-hydroxy-10-oxidophenoxazin-10ium-3-one, diffuses into the cytosol and acts as an intermediate electron acceptor allowing the
oxidised blue non-fluorescent form to be reduced by both mitochondrial and cytosolic

enzyme activity to the fluorescent pink one which is easily measured by its absorption or
fluorescence. [47, 48, 50]
Its response is thus considered the expression of general cellular metabolism. Therefore,
although reduced conversion compared to controls is used as a measure of reduced cellular
viability for both AB and MTT assays; the MTT response is more specifically sensitive to
mitochondrial enzymes while AB is related to both mitochondrial and cytosolic activities.
As illustrated by Figure 2, A549 cells and Calu-1 exhibit somewhat different IC50 values, as
measured using the MTT cytotoxicity assay, determined to be 0.55±0.16 µM and 0.90 ±0.24
µM for the A549 and Calu-1 cell lines respectively. The most notable differences observed,
however, are in the AB cytotoxicity profiles, which are characterised by IC50 values of 0.42
±0.06 µM and 0.69 ± 0.13 µM for the A549 and Calu-1 cell lines respectively. For the same
DOX dosage, although similar changes in mitochondrial activity (as recorded by the MTT
assay) and the overall cellular metabolism (as recorded by the AB assay) are observed for the
A549 cell line, the overall dose dependent change in cellular metabolism, as recorded by the
AB assay, is considerably less in the Calu-1 cell line.
The differing cytotoxic profiles for the two cell lines, is consistent with the contribution of
multiple mechanisms to the toxic response, and a greater intrinsic resistance of the Calu-1
cell line to one or more of these mechanisms. The underlying mechanisms will be studied in
more detail in the following sections. Since cells will be analysed after 24h exposure, the IC50
determined using the MTT assay was used for the rest of the study, for both cell lines.

Figure 2: MTT 24 hrs dose dependent cytotoxicity of DOX to A549 and Calu-1

Confocal Laser Scanning Fluorescence Microscopy:
A.

B.

Figure 3: Confocal Laser Scanning Fluorescence images of A. A549 and B. Calu-1 after 24h
DOX exposure and Nucred® staining confirming the DOX nuclear localisation.

CLSM was employed to visualise the DOX intracellular internalisation and localisation in
both cell lines. Figure 3 illustrates the images for A549 and Calu-1 cells after 24hr DOX
exposure, at the respective MTT IC50 concentration for each cell line, and Nucred® staining.
DOX is predominantly localised on the nuclear area and, for both cell lines after exposure,
cells appear smaller in size and round or oval in shape and exhibit noticeable nucleoli
fragmentation, known as karyorrhexis, and membrane blebbing. The cytoplasm is more
tightly packed as a result of cellular shrinkage. All these morphological changes indicate that
cells are going under apoptosis. [28, 29, 51-54]

Using ImageJ software, after fluorescence background subtraction, the mean fluorescence
intensity of the nuclear area was measured for 10 cells for each cell line. The average DOX
fluorescence intensity was determined to be, respectively 644±29 AU for the A549 cell line
and 725±11 AU for Calu-1, indicating that a larger amount of DOX is present in the Calu-1
nucleus, despite the fact that the IC50 value for Calu-1 is almost twice that of A549 and the
global nuclear volume is slightly higher for A549 than Calu-1. [42]

Flow Cytometry and bcl-2 expression:
Bcl-2 is an intracellular nuclear membrane anti apoptotic protein synthetised in direct
response to DNA damage, in this case due to intercalation of DOX. As shown in Figure 4, a
similar expression profile of up regulation followed by down regulation of the bcl-2 protein,
as a function of DOX concentration, was observed for the two cell lines and this expression
profile has been reported to be responsible for the resistance to apoptosis up to certain doses,
above which DNA damage becomes prominent and bcl-2 levels decrease as cells enter
apoptosis.[55]
A.

B.

Figure 4: Expression level of bcl-2 due to DOX exposure and control healthy cells for A.
A549 and B. Calu-1 determined by Flow Cytometry.
The differences between the two bcl-2 expression profiles for each cell line, as a function of
MTT IC50 are manifest in the maximum level of bcl-2, and the dose at which this is reached.
It is notable that the bcl-2 level in Calu-1 cells is consistently higher over the dose range than
A549, with a maximum expression at 2 IC50 for A549 (1.1M) and 3 IC50 for Calu-1
(2.7M).

ROS production monitored by DCFDA:
In addition to the mode of action of DNA intercalation, internalised DOX can also lead to the
generation of intracellular ROS in the cytosol by redox activation in the presence of NADPH,
forming a quinone radical via one electron transfer and generating peroxide and superoxide,
[56, 57] resulting in DNA, mitochondrial and cell membrane damage by oxidation,
responsible for its most significant chronic side effect, cardiotoxicity. [58, 59]
ROS were measured by the DCFDA dye, a highly fluorescent compound in presence of ROS
which can be detected by fluorescence. As detailed in Table 1, and illustrated schematically
in Figure 5, significantly higher ROS levels are present in Calu-1 cells than A549 (Test
(DOX+DCFDA)), after 24 hr exposure to the DOX IC50 concentration, as measured by the
MTT assay. In fact, Calu-1 has higher ROS levels compared to A549 even without any DOX
exposure and this expression becomes even higher after DOX exposure, emphasising the
difference between the two cell lines. ROS are usually generated through a cascade of
reactions resulting from the distinct oxidation status of O2, including its radical forms, such as

the superoxide radical, and non-radical forms such as hydrogen peroxide, H2O2. [60] Cancer
cells have a high level of ROS, recognized to be signalling molecules in various biological
processes, eliciting proliferation, genomic instability and inflammation[61] but a considerable
increase of ROS level induces damage and promotes apoptosis. [59, 61] Although the
relationship between DNA mutations, ROS generation, and drug sensitivity remains unclear,
the ROS mediated apoptosis mechanism appears to be activated in the Calu-1 cell line to a
significantly greater extent than in A549.

Table 1: ROS production in A. A549 cell line and B. Calu-1 cell line, negative controls using
healthy cells and no DCFDA, exposed cells and no DCFDA and healthy cells with DCFDA
and H2O2 1 µM solution as positive control
A.

Average
STD
Ave %
STD %

Negative controls (Arb.Units)
Healthy
DOX + PBS Negative
cells +PBS
(no
control
(no
DCFDA)
(healthy cells
DCFDA)
+DCFDA)
70.85706
254.6403
80.57879
10.88444
12.0606
6.892106
87.93512
316.014
100
13.50783
14.96746
8.55325

Positive control
(Cells+H2O2+
DCFDA)
(Arb. Units)

Test
(DOX+DCFDA)
(Arb. Units)

190.1014
28.31797
235.9199
35.14321

279.9507
25.60829
347.4248
31.78044

Negative controls
DOX + PBS Negative
(no
control
DCFDA)
(healthy cells
+DCFDA)
312.8539
309.0865
23.91193
21.34131
101.2189
100
7.736324
6.90464

Positive
control
(Cells+H2O2+
DCFDA)

Test
(DOX+DCFDA)

356.7716
24.93965
115.4277
8.068825

1214.652
63.87997
392.9813
20.66734

B.
Healthy
cells +PBS
(no
DCFDA)
Average 47.589
STD
10.91059
Ave %
15.39666
STD % 3.529947

Figure 5: Reactive oxygen species generation expressed on percentage of control for Calu-1
and A549 cell lines.
Raman micro spectroscopy:
Raman spectrosopy has previously demonstrated that A549 and Calu-1 cells are
distinguishable, based on the spectral profile of their nucleoli. [42] Furthermore, it has
previously been employed to profile the interactions of DOX within the nuclear and nucleolar
regions of A549 cells. [14] In order to further elucidate the subcellular differences of the
responses and potential resistance mechanisms of the A549 and Calu-1 cell lines to DOX
exposure, Raman spectra, for both A549 and Calu-1 cells, were taken from the three cellular
compartments after 24hrs exposure to the MTT IC50 concentration of DOX corresponding to
each cell line. For PCA analysis, figures corresponding to spectral differentiation according
to PC1 and PC2 were plotted and, for clarity, the corresponding loadings are off set, and the
dashed horizontal line in all cases indicating zero loading.
Figure 6 shows the mean spectra of nucleolus, nucleus and cytoplasm for Calu-1 cell lines
along with the spectrum of DOX powder dissolved in sterile water. Nucleolar size for both
control cell lines is of the order of 2–4 μm, although it reduces to ~ 1-2 μm due to DOX
exposure inducing fragmentation (Figure 3) [ref]. Nevertheless, it remains larger than the
Raman laser spot (1 μm), allowing Raman spectra acquisition specifically from the nucleoli.

Figure 6: Spectrum of Doxorubicin (A) and mean spectra of Nucleolus (B), Nucleus (C) and
Cytoplasm (D) of the Calu-1 cell line, highlighted regions indicating discriminating
Doxorubicin features.
As shown in previous study of the A549 cell line by Farhane et al. [14], and as seen in Figure
6 for the Calu-1 cell line, obvious DOX features (indicated by highlighted regions) at 440 and
465 cm−1 respectively C–C–O and C–O and 1085, 1215 and 1245 cm−1 related to C–O, C–O–
H and C–H are observed in the nucleolar and nuclear region for both cell lines, confirming
the predominant localisation of the drug in these regions.

Figure 7: Mean spectra of the nucleoli of Calu-1 cells highlighting the spectroscopic changes
after DOX exposure; control (brown) and after DOX exposure (black)

Additionally, in the mean spectra of the nucleolus of Calu-1, before and after DOX exposure,
an evident diminishment of peaks at 847 and 960 cm-1 can be seen (highlighted in Figure 7),
indicating a modification of ribose phosphate backbone due to DOX intercalation. Moreover,
obvious decreases of DNA peaks at 669, 728, 782 and 830 cm-1 in the spectra of the
nucleolus of treated cells compared to non-treated ones are observed, due to DOX-DNA
interactions inducing DNA synthesis interruption [57] and changes in DNA conformation
(decrease of DNA B form) [62] inducing early cell apoptosis. [54, 63] (Similar results were
found for nuclear spectra, data not shown). In addition to the decrease in DNA peaks, a shift
towards lower wavenumbers is observed for the peak at 1095 cm-1, corresponding to O-P-O
stretching, which indicates that DOX is also able to bind to DNA externally. [62] Besides the
effects on DNA related spectral features, it appears that proteins and lipids are also affected,
as evidenced by the decrease of their corresponding peaks, for example, respectively at 1450
and 1665 cm-1. The peak at 1450 cm-1 is influenced by DOX peak proximity but, after DOX
subtraction, it can be clearly seen that this peak is diminished (data not shown). [64]
A more detailed analysis of the changes in the spectral features as a result of DOX exposure
and comparison between the responses of the two cell lines is facilitated by PCA. Figure 8,
showing PCA of nucleolar, nuclear and cytoplasmic regions, for A549 and Calu-1 cells after
exposure to DOX, exhibits a separation between the three cellular compartments and the
corresponding loading of PC1, differentiating the combined nuclear region from the
cytoplasmic one, is dominated on the positive side by DOX features, confirming once again
its predominantly nuclear and nucleolar subcellular localisation, for both cell lines. The
negative side is dominated by lipidic features at 1450 cm-1 (CH2 deformation) and 1661 cm-1
(Lipids C=C stretching), corresponding to biochemical changes in the cytoplasmic region.
[13, 65, 66]

A.

B.

Figure 8: PCA of nucleolar, nuclear and cytoplasmic regions of A. A549 and Calu-1 with
corresponding loadings of PC1 and PC2 B. PCA of each cell localisation for A549 and Calu1 and the corresponding loadings of PC1 and PC2
Nucleolus

Nucleus

Cytoplasm

A549 cell line

Nucleolus

Nucleus

Cytoplasm

Calu-1 cell line

A pairwise PCA of the three cellular regions was performed, and it is notable in Figure 8B,
that PC1 clearly differentiates the nucleolar and nuclear regions between the two cell lines
and the corresponding loading of PC1 clearly exhibits positive DOX features, indicating that
there is more DOX in Calu-1 than in A549 cells, supporting the ImageJ analysis of the CLSM

images. Negatives features at 1320 and 1450 cm-1 (CH2 deformation) and 1661 cm-1 (Lipid
C=C stretching) are also observed in the loading of PC1 for nucleolar, nuclear and
cytoplasmic areas, indicating that there is higher lipidic content in A549 cells than in Calu-1.

Figure 9: PCA of nucleolar compartment of Calu-1 and A549 after DOX spectral features
subtraction and corresponding loadings of PC1 and PC2
Nucleolus

A549 cell line after DOX subtraction

Nucleolus

Calu-1 cell line after DOX subtraction

The differing cellular responses, in the subcellular regions, can be better visualised after
subtraction of the DOX spectral signature from the cellular spectra. [14] Figure 9 shows the
PCA of the nucleolus of A549 and Calu-1 after subtraction of DOX spectral features.
Although the differentiation is not absolute, the A549 data is predominantly distributed with
positive loadings of PC1, and vice versa for Calu-1. The loading of PC1 indicates that there is
a more pronounced increase in some protein features in Calu-1 cells, than in A549. These
include those at 645 cm-1 (C–C twist Tyrosine), 936 cm-1 (C–C stretching), 1176 cm-1
(Tyrosine), 1450 cm-1 (C-H) and 1665 cm-1 (Amide I). Similar changes are apparent in these
protein related features in the mean spectra of Figure 6, although they are less pronounced in
the mean spectra of A549. [14]
A further notable difference in the Raman profiles of Calu-1 compared to A549 cells is seen
in the cytoplasmic region. Figure 6 reveals traces of DOX features for Calu-1, most apparent
in the region from ~400-450 cm-1, which suggests the presence of a small amount of DOX in
the cytoplasm, undetectable by CLSM. These are completely absent in the case of A549. [14]
The same DOX features are obvious in the loading of PC2, separating the two cytoplasmic
regions, in Figure 8B, further indicating the presence of DOX in the cytoplasm of Calu-1

cells, while it is not detectable in A549. This observation highlights the sensitivity of Raman
spectroscopic profiling to even small quantities of drugs inside cells and indicates that the
sub-cellular distribution of DOX after 24hr exposure differs between the two cell lines.
In order, to investigate the DOX mechanism of action in more details, and to support and
complement the PCA observations, ICA was performed using three components, as estimated
by PCA, explaining the majority of variance, and only the first conponent for each cellular
compartment was plotted and off set for clarity.

Figure 10: A. DOX spectrum and A549 ICA component B. Nucleolus C. Nucleus and D.
Cytoplasm
Figures 10 and 11 represent the ICA signals for the nucleolar, nuclear and cytoplasmic
regions, respectively for the A549 and Calu-1 cell lines, plotted with the raw DOX spectrum
for comparison. It is notable that the nucleolar and nuclear components exhibit DOX features
at 440, 465 cm−1, 1085, 1215 and 1245 cm−1 for both cell lines, while these features are only
strongly observed (Figure 11) in the cytoplasm of Calu-1, confirming the PCA results.

Figure 11: A. DOX spectrum and Calu-1 ICA component B. Nucleolus C. Nucleus and D.
Cytoplasm

In both Figure 10 and 11, the peak at 795 cm-1 in the IC for both the nucleolus and nucleus
(absent in the cytoplasm) corresponds to nucleic acid and confirms the nucleic DOX
intercalation, while the negative peak at 1665cm-1 represents a decrease in the protein Amide
I response, consistent with the analysis of the mean spectrum of nucleolus and nucleus before
and after DOX exposure. The IC for both the nucleolus and nucleus also exhibit obvious
features at 1430-1456 cm-1. These peaks are not visible in mean spectra, due to the proximity
of lipid peaks and are absent in ICA of the control cells before exposure to DOX (data not
shown). While these signatures could be attributed to DOX, they also correspond to
signatures of Guanine and Cytosine. [67] The increase in these nucleic acid signatures could
be due to DOX-DNA intercalation. DOX intercalates preferentially between two adjacent GC
bases [20], inducing changes in DNA conformation, damage of the DNA double helix
structure and the observed spectral changes may therefore be evidence of DOX intercalation
between Guanine and Cytosine bases. There is also a hyperchromic effect observed for the
peak at 1376 cm-1 corresponding to Thymine, Adenine, Guanine (ring breathing modes of the
DNA/RNA bases). [68-70]

Figure 12: A. Spectrum DOX and B. Cytoplasm Calu-1 cell line ICA component.

In the ICA of the cytoplasm of DOX exposed Calu-1 cells (Figure 12), DOX features are
clearly evident, confirming DOX localisation in the cytoplasm. However, the spectral profile
of the IC is considerably different than that of pristine DOX, and the IC of the nuclear and
nucleolar regions. This is consistent with a metabolisation of the DOX molecules within the
cytoplasm, and the resultant cellular interaction is manifest as the spectral features at 720 and
877 cm-1 corresponding to C–C–N+ stretching, ones at 1024, 1343 cm-1 and 1456 cm-1,
related to C-H vibrations and 1661 cm-1, corresponding to lipidic C=C stretching. [14, 71]

Discussion
The analysis of the dose dependent cytotoxic response of the two cell lines to DOX exposure,
after 24 hrs shows a notably different profile, particularly for the case of the Alamar Blue
assay. The results are consistent with an increased resistance of the Calu-1 cell line to the
drug, compared to A549. The traditional cytotoxic assays shed little light on the origin of the
different cellular responses, in terms of the cellular pharmacokinetics, however. The flow
cytometric analysis indicates that DOX exposure elicits significantly higher upregulation of
the anti-apoptotic protein bcl-2 in the Calu-1 cell line, while analysis of the induced oxidative
stress reveals substantially higher levels of ROS in Calu-1.
DOX is reported to induce cell death by two principle modes of action, and the results are
consistent with different relative contributions to the cytotoxic response in the two cell lines.

DOX is rapidly trafficked to the cell nucleus (and mitochondria), where it binds with the
DNA by intercalation, inducing DNA damage and initiating an apoptotic cascade, registered
by the MTT assay. The MTT assay registers similar cytotoxicity profiles for the two cell
lines, and the somewhat higher IC50 value for Calu-1 is consistent with the observation from
CLSM that there is a higher uptake of DOX in the nuclei of Calu-1. The DNA damage in cell
nuclei triggers the upregulation of the anti-apoptotic protein bcl-2, which inhibits the
apoptotic process. This response is significantly stronger in the Calu-1 cell line, and this
greater resistance to apoptosis is consistent with the substantially lower loss of cell viability
as registered by the AB assay. Concomitantly, a significantly higher degree of oxidative
stress in the Calu-1 cell line is observable. ROS generation in the cytosol, resulting in DNA
damage in the nucleus, is the second reported mode of action of DOX. The process is the
result of a complex cascade initiated by the reduction of DOX in the presence of NADPH
and, in comparison to the direct interaction of DOX with the nuclear DNA, is a relatively
slow process.
The combination of the cytotoxic assays, Flow Cytometry and CLSM can help to understand
the underlying mechanisms of the different responses of the two cell lines to DOX exposure,
and the apparent higher resistance one to cell death. As a label free, high content analysis
technique, Raman spectroscopy can provide similar insights in a single measurement.
Notably, Raman spectroscopy gives a clear indication of the presence of DOX and/or its
semiquinone metabolite in the cytoplasm of Calu-1 cells, whereas it is not apparent in A549
cells. This observation is indicative of a retarded transport of the drug to the nuclei of Calu-1
cells, and an increased contribution of oxidative stress to the cellular response mechanism.
Contained in the spectral changes of the cytoplasm are also signatures of cell damage,
characteristic of the response mechanism. In the cell nuclei, DOX exposure produces clear
signatures of DNA intercalation, as well as external groove binding, in both cell lines. In the
nuclei of Calu-1 cells, there is a significantly higher increase in protein activity, consistent
with the upregulation of the cellular anti-apoptotic resistance mechanism.
The results of the Raman micro spectroscopic investigation therefore clearly demonstrate
signatures of the interaction of the DOX with the two cell lines, and the mechanisms of
cellular response. The differences in response are consistent with the differences observed
through the combination of established techniques of cytotoxic assays, flow cytometry and
CLSM.

However, the spectroscopic signatures are obtained in a single, label free measurement. It is
noted that the chemotherapeutic agent chosen here, DOX, is a relatively strong Raman
scatter, due to is -conjugated anthracycline structure, and much is already known about its
mechanisms of interaction. Nevertheless, the study serves as a further illustration of the
potential of Raman spectroscopy as an in vitro companion diagnostic tool. Although the
screening was performed at a single time point, ongoing technological developments such as
in nonlinear Raman techniques promise significantly enhanced signals, and therefore reduced
sampling times, and ultimately real time monitoring of cellular uptake of drugs and other
external agents such as nanoparticles, and the subsequent cellular responses.
Conclusion:
The study further demonstrates the potential of Raman micro spectroscopy as a high content,
label free in vitro tool, not only to localise drugs within cells, but also to monitor their
interactions in the cytoplasm and nucleus of the cells at a molecular level, and to characterise
the subsequent cellular responses on a subcellular level. Spectroscopic signatures of DNA
intercalation, binding and damage are clearly identifiable in the cell nucleus, and cellular
responses such as the upregulation of anti-apoptotic proteins and cytoplasmic damage can be
monitored. The technique has previously been employed to differentiate the two cancer cell
lines, A549 and Calu-1 based on the spectroscopic signatures of their nucleoli, and in this
study the differences of the responses of the two cell lines to DOX exposure are clearly
identifiable in their post exposure spectroscopic signatures. Notably, due to the sensitivity of
the detection system, Raman spectroscopy can detect the presence of the drug in the
cytoplasm in the Calu-1 cell line, but not in A549, which is a key to understanding the
difference in the cytotoxic responses, and therefore in cell resistance to the drug, coupled
with the increased upregulation of anti-apoptotic proteins in the nucleus. The technique
corroborates the results of classic cytotoxicity assays, bcl-2 monitoring using flow cytometry,
ROS monitoring using confocal microscopy, but does so in a single, label free measurement,
clearly indicating the benefits of the technique for high content screening and in vitro
companion diagnostics.
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Graphical Abstract:

Raman microspectroscopy is employed to investigate and compare the in vitro mechanisms
of action of Doxorubicin and cellular resistances of cancer cell lines A549 and Calu-1.
Results show the potential of Raman not only to distinguish the different mechanisms of
action and subcellular response but also to elucidate drug resistance in the different cell lines.

